GlassScriptPhysician profile
Allison Hayes
NPI 1659602233
$1,130.34
in general payments reported to CMS, 2019-2025
12 companies · $470 in 2025
The $470 reported for 2025 was more than what 76% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $370 · 2022: $100 · 2023: $102 · 2024: $88.72 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $389.20 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $194.83 | 2025 | |
| Lundbeck LLC | $110.57 | 2021 | |
| Sun Pharmaceutical Industries INC. | $97.77 | 2021-2025 | |
| Galderma Laboratories, L.P. | $90.87 | 2022-2025 | Aklief, Nemluvio |
| Incyte Corporation | $52.74 | 2021-2024 | Opzelura |
| Takeda Pharmaceuticals U.S.A., INC. | $52.41 | 2024-2025 | Livtencity |
| Lilly USA, LLC | $44.10 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $43.77 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.65 | 2024 | Spevigo |
| Vyne Pharmaceuticals INC. | $17.77 | 2021 | |
| Ucb, INC. | $14.66 | 2025 | Bimzelx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Hayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.